UCB SA 2019 IR
The report highlights UCB's progress in its "Accelerate and Expand" strategic phase during 2019, delivering a 6% revenue increase to €4.913 billion. The company successfully launched two new products, Evenity and Nayzilam, and advanced its clinical pipeline with five new Phase 3 programs. UCB also made significant progress toward its 2030 green goals, achieving a 35% reduction in CO2 emissions compared to its 2015 baseline. Additionally, the company entered into an agreement to acquire Ra Pharmaceuticals to strengthen its rare disease portfolio.
Company: UCB SA
Sector: Health Care
Country: Belgium
Year: 2019
Type: IR
Pages: 241
UCB SA
Integrated Annual Report
The report highlights UCB's progress in its "Accelerate and Expand" strategic phase during 2019, delivering a 6% revenue increase to €4.913 billion. The company successfully launched two new products, Evenity and Nayzilam, and advanced its clinical pipeline with five new Phase 3 programs. UCB also made significant progress toward its 2030 green goals, achieving a 35% reduction in CO2 emissions compared to its 2015 baseline. Additionally, the company entered into an agreement to acquire Ra Pharmaceuticals to strengthen its rare disease portfolio.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2019
Reporting Period
Jan 1, 2019 - Dec 31, 2019
Fiscal Year
2019
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Net Zero Target
Employees